# A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).

> **NCT05608681** · PHASE1,PHASE2 · RECRUITING · sponsor: **Eupraxia Pharmaceuticals Inc.** · enrollment: 117 (estimated)

## Conditions studied

- Eosinophilic Esophagitis

## Interventions

- **DRUG:** EP-104GI
- **OTHER:** Matching vehicle control

## Key facts

- **NCT ID:** NCT05608681
- **Lead sponsor:** Eupraxia Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-31
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 117 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05608681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05608681, "A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05608681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*